122 results on '"Phillips, Richard O."'
Search Results
2. Impaired T-cell response to phytohemagglutinin (PHA) in tuberculosis patients is associated with high IL-6 plasma levels and normalizes early during anti-mycobacterial treatment
- Author
-
Vivekanandan, Monika M., Adankwah, Ernest, Aniagyei, Wilfred, Acheampong, Isaac, Minadzi, Difery, Yeboah, Augustine, Arthur, Joseph F., Lamptey, Millicent, Abass, Mohammed K., Kumbel, Francis, Osei-Yeboah, Francis, Gawusu, Amidu, Debrah, Linda Batsa, Owusu, Dorcas O., Debrah, Alexander, Mayatepek, Ertan, Seyfarth, Julia, Phillips, Richard O., and Jacobsen, Marc
- Published
- 2023
- Full Text
- View/download PDF
3. Plasma cytokine levels characterize disease pathogenesis and treatment response in tuberculosis patients
- Author
-
Vivekanandan, Monika M., Adankwah, Ernest, Aniagyei, Wilfred, Acheampong, Isaac, Yeboah, Augustine, Arthur, Joseph F., Lamptey, Millicent N. K., Abass, Mohammed K., Gawusu, Amidu, Kumbel, Francis, Osei-Yeboah, Francis, Debrah, Linda Batsa, Owusu, Dorcas O., Debrah, Alexander, Mayatepek, Ertan, Seyfarth, Julia, Phillips, Richard O., and Jacobsen, Marc
- Published
- 2023
- Full Text
- View/download PDF
4. Diminished Interleukin-7 receptor expression on T-cell subsets in tuberculosis patients
- Author
-
Acheampong, Isaac, Minadzi, Difery, Adankwah, Ernest, Aniagyei, Wilfred, Vivekanandan, Monika M., Yeboah, Augustine, Arthur, Joseph F., Lamptey, Millicent, Abass, Mohammed K., Kumbel, Francis, Osei-Yeboah, Francis, Gawusu, Amidu, Laing, Edwin F., Batsa Debrah, Linda, Owusu, Dorcas O., Debrah, Alexander, Mayatepek, Ertan, Seyfarth, Julia, Phillips, Richard O., and Jacobsen, Marc
- Published
- 2023
- Full Text
- View/download PDF
5. Impact of antibiotic intake on the incidence of extended-spectrum β-lactamase–producing Enterobacterales in sub-Saharan Africa: results from a community-based longitudinal study
- Author
-
Heinemann, Melina, Kleinjohann, Lukas, Rolling, Thierry, Winter, Doris, Hackbarth, Nina, Ramharter, Michael, Addo, Marylyn, Eibach, Daniel, Phillips, Richard O., Owusu-Ofori, Alex, and Vinnemeier, Christof D.
- Published
- 2023
- Full Text
- View/download PDF
6. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
- Author
-
Blach, Sarah, Terrault, Norah A, Tacke, Frank, Gamkrelidze, Ivane, Craxi, Antonio, Tanaka, Junko, Waked, Imam, Dore, Gregory J, Abbas, Zaigham, Abdallah, Ayat R, Abdulla, Maheeba, Aghemo, Alessio, Aho, Inka, Akarca, Ulus S, Alalwan, Abduljaleel M, Alanko Blomé, Marianne, Al-Busafi, Said A, Aleman, Soo, Alghamdi, Abdullah S, Al-Hamoudi, Waleed K, Aljumah, Abdulrahman A, Al-Naamani, Khalid, Al Serkal, Yousif M, Altraif, Ibrahim H, Anand, Anil C, Anderson, Motswedi, Andersson, Monique I, Athanasakis, Kostas, Baatarkhuu, Oidov, Bakieva, Shokhista R, Ben-Ari, Ziv, Bessone, Fernando, Biondi, Mia J, Bizri, Abdul Rahman N, Brandão-Mello, Carlos E, Brigida, Krestina, Brown, Kimberly A, Brown, Jr, Robert S, Bruggmann, Philip, Brunetto, Maurizia R, Busschots, Dana, Buti, Maria, Butsashvili, Maia, Cabezas, Joaquin, Chae, Chungman, Chaloska Ivanova, Viktorija, Chan, Henry Lik Yuen, Cheinquer, Hugo, Cheng, Kent Jason, Cheon, Myeong-Eun, Chien, Cheng-Hung, Chien, Rong-Nan, Choudhuri, Gourdas, Christensen, Peer Brehm, Chuang, Wan-Long, Chulanov, Vladimir, Cisneros, Laura E, Coco, Barbara, Contreras, Fernando A, Cornberg, Markus, Cramp, Matthew E, Crespo, Javier, Cui, Fuqiang, Cunningham, Chris W, Dagher Abou, Lucy, Dalgard, Olav, Dao, Doan Y, De Ledinghen, Victor, Derbala, Moutaz F, Deuba, Keshab, Dhindsa, Karan, Djauzi, Samsuridjal, Drazilova, Sylvia, Duberg, Ann-Sofi, Elbadri, Mohammed, El-Sayed, Manal H, Esmat, Gamal, Estes, Chris, Ezzat, Sameera, Färkkilä, Martti A, Ferradini, Laurent, Ferraz, Maria Lucia G, Ferreira, Paulo R A, Filipec Kanizaj, Tajana, Flisiak, Robert, Frankova, Sona, Fung, James, Gamkrelidze, Amiran, Gane, Edward, Garcia, Virginia, García-Samaniego, Javier, Gemilyan, Manik, Genov, Jordan, Gheorghe, Liliana S, Gholam, Pierre M, Goldis, Adrian, Gottfredsson, Magnus, Gray, Richard T, Grebely, Jason, Gschwantler, Michael, Hajarizadeh, Behzad, Hamid, Saeed S, Hamoudi, Waseem, Hatzakis, Angelos, Hellard, Margaret E, Himatt, Sayed, Hofer, Harald, Hrstic, Irena, Hunyady, Bela, Husa, Petr, Husic-Selimovic, Azra, Jafri, Wasim S M, Janicko, Martin, Janjua, Naveed, Jarcuska, Peter, Jaroszewicz, Jerzy, Jerkeman, Anna, Jeruma, Agita, Jia, Jidong, Jonasson, Jon G, Kåberg, Martin, Kaita, Kelly D E, Kaliaskarova, Kulpash S, Kao, Jia-Horng, Kasymov, Omor T, Kelly-Hanku, Angela, Khamis, Faryal, Khamis, Jawad, Khan, Aamir G, Khandu, Lekey, Khoudri, Ibtissam, Kielland, Knut B, Kim, Do Young, Kodjoh, Nicolas, Kondili, Loreta A, Krajden, Mel, Krarup, Henrik Bygum, Kristian, Pavol, Kwon, Jisoo A, Lagging, Martin, Laleman, Wim, Lao, Wai Cheung, Lavanchy, Daniel, Lázaro, Pablo, Lazarus, Jeffrey V, Lee, Alice U, Lee, Mei-Hsuan, Li, Michael K K, Liakina, Valentina, Lim, Young-Suk, Löve, Arthur, Lukšić, Boris, Machekera, Shepherd Mufudzi, Malu, Abraham O, Marinho, Rui T, Maticic, Mojca, Mekonnen, Hailemichael D, Mendes-Correa, Maria Cássia, Mendez-Sanchez, Nahum, Merat, Shahin, Meshesha, Berhane Redae, Midgard, Håvard, Mills, Mike, Mohamed, Rosmawati, Mooneyhan, Ellen, Moreno, Christophe, Muljono, David H, Müllhaupt, Beat, Musabaev, Erkin, Muyldermans, Gaëtan, Nartey, Yvonne Ayerki, Naveira, Marcelo C M, Negro, Francesco, Nersesov, Alexander V, Njouom, Richard, Ntagirabiri, Rénovat, Nurmatov, Zuridin S, Obekpa, Solomon A, Oguche, Stephen, Olafsson, Sigurdur, Ong, Janus P, Opare-Sem, Ohene K, Orrego, Mauricio, Øvrehus, Anne L, Pan, Calvin Q, Papatheodoridis, George V, Peck-Radosavljevic, Markus, Pessoa, Mário G, Phillips, Richard O, Pimenov, Nikolay, Plaseska-Karanfilska, Dijana, Prabdial-Sing, Nishi N, Puri, Pankaj, Qureshi, Huma, Rahman, Aninda, Ramji, Alnoor, Razavi-Shearer, Devin M, Razavi-Shearer, Kathryn, Ridruejo, Ezequiel, Ríos-Hincapié, Cielo Y, Rizvi, S M Shahriar, Robaeys, Geert K M M, Roberts, Lewis R, Roberts, Stuart K, Ryder, Stephen D, Sadirova, Shakhlo, Saeed, Umar, Safadi, Rifaat, Sagalova, Olga, Said, Sanaa S, Salupere, Riina, Sanai, Faisal M, Sanchez-Avila, Juan F, Saraswat, Vivek A, Sarrazin, Christoph, Sarybayeva, Gulya, Seguin-Devaux, Carole, Sharara, Ala I, Sheikh, Mahdi, Shewaye, Abate B, Sievert, William, Simojoki, Kaarlo, Simonova, Marieta Y, Sonderup, Mark W, Spearman, C Wendy, Sperl, Jan, Stauber, Rudolf E, Stedman, Catherine A M, Su, Tung-Hung, Suleiman, Anita, Sypsa, Vana, Tamayo Antabak, Natalia, Tan, Soek-Siam, Tergast, Tammo L, Thurairajah, Prem H, Tolmane, Ieva, Tomasiewicz, Krzysztof, Tsereteli, Maia, Uzochukwu, Benjamin S C, Van De Vijver, David A M C, Van Santen, Daniela K, Van Vlierberghe, Hans, Van Welzen, Berend, Vanwolleghem, Thomas, Vélez-Möller, Patricia, Villamil, Federico, Vince, Adriana, Waheed, Yasir, Weis, Nina, Wong, Vincent W-S, Yaghi, Cesar G, Yesmembetov, Kakharman, Yosry, Ayman, Yuen, Man-Fung, Yunihastuti, Evy, Zeuzem, Stefan, Zuckerman, Eli, and Razavi, Homie A
- Published
- 2022
- Full Text
- View/download PDF
7. Genetic diversity of SARS-CoV-2 infections in Ghana from 2020-2021
- Author
-
Morang’a, Collins M., Ngoi, Joyce M., Gyamfi, Jones, Amuzu, Dominic S. Y., Nuertey, Benjamin D., Soglo, Philip M., Appiah, Vincent, Asante, Ivy A., Owusu-Oduro, Paul, Armoo, Samuel, Adu-Gyasi, Dennis, Amoako, Nicholas, Oliver-Commey, Joseph, Owusu, Michael, Sylverken, Augustina, Fenteng, Edward D., M’cormack, Violette V., Tei-Maya, Frederick, Quansah, Evelyn B., Ayivor-Djanie, Reuben, Amoako, Enock K., Ogbe, Isaac T., Yemi, Bright K., Osei-Wusu, Israel, Mettle, Deborah N. A., Saiid, Samirah, Tapela, Kesego, Dzabeng, Francis, Magnussen, Vanessa, Quaye, Jerry, Opurum, Precious C., Carr, Rosina A., Ababio, Patrick T., Abass, Abdul-Karim, Akoriyea, Samuel K., Amoako, Emmanuella, Kumi-Ansah, Frederick, Boakye, Oliver D., Mibut, Dam K., Odoom, Theophilus, Ofori-Boadu, Lawrence, Allegye-Cudjoe, Emmanuel, Dassah, Sylvester, Asoala, Victor, Asante, Kwaku P., Phillips, Richard O., Osei-Atweneboana, Mike Y., Gyapong, John O., Kuma-Aboagye, Patrick, Ampofo, William K., Duedu, Kwabena O., Ndam, Nicaise T., Bediako, Yaw, Quashie, Peter K., Amenga-Etego, Lucas N., and Awandare, Gordon A.
- Published
- 2022
- Full Text
- View/download PDF
8. Haematological Profile and ACE2 Levels of COVID-19 Patients in a Metropolis in Ghana.
- Author
-
Ackah, Ezekiel B., Owusu, Michael, Sackey, Benedict, Boamah, Justice K., Kamasah, Japhet S., Aduboffour, Albert A., Akortia, Debora, Nkrumah, Gifty, Amaniampong, Andrews, Klevor, Nicholas, Agyemang, Lawrence D., Ayisi-Boateng, Nana K., Sylverken, Augustina, Phillips, Richard O., and Owusu-Dabo, Ellis
- Subjects
CORONAVIRUS diseases ,HEMATOLOGY ,SARS disease ,ANGIOTENSIN converting enzyme - Abstract
Background: Several studies have linked coronavirus disease 2019 (COVID-19) risk to age and ABO blood groups. Variations in plasma angiotensin-converting enzyme 2 (ACE2) levels and blood counts have been reported, suggesting an association between disease severity and low lymphocyte levels. Aim: this study aimed to understand how these factors relate to COVID-19 in Ghanaian patients, considering geographical and demographic differences. Methods: Participants were recruited from six hospitals in Kumasi, Ghana, between June 2020 and July 2021. Nasopharyngeal swabs were taken to test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and blood samples were collected for complete blood count testing, ABO/Rhesus typing, and assessment of plasma ACE2 levels. Demographic and COVID-19 severity data were gathered, and IBM SPSS version 25.0 was used for analysis. Results: Overall, 515 patients were enrolled, out of which 55.9% (n = 288/515) were males and 50.3% (n = 259/515) tested positive for SARS-CoV-2. The median age was 37 years (IQR = 26–53). Age was significantly associated with SARS-CoV-2 infection (p = 0.002). The severe COVID-19 group was the oldest (70 years, IQR = 35–80) and presented with anaemia (haemoglobin, g/dL: 9.55, IQR = 7.85–11.93), leukocytosis (WBC × 10
3 /μL: 15.87, IQR = 6.68–19.80), neutrophilia (NEUT × 106 /μL: 14.69, IQR = 5.70–18.96) and lymphocytopenia (LYMPH × 106 /μL: 0.47, IQR = 0.22–0.66). No association was found between SARS-CoV-2 positivity and ABO (p = 0.711) or Rh (p = 0.805) blood groups; no association was also found between plasma ACE2 levels and SARS-CoV-2 status (p = 0.079). However, among COVID-19 participants, plasma ACE2 levels were significantly reduced in the moderate illness group (40.68 ng/mL, IQR = 34.09–48.10) compared with the asymptomatic group (50.61 ng/mL, IQR = 43.90–58.61, p = 0.015). Conclusions: While there may be no real association between the ABO blood group, as well as plasma ACE2 levels, and SARS-CoV-2 infection in Ghanaian patients, older individuals are at a higher risk of severe disease. Anaemia, and leukocytosis with lymphocytopenia may be indicators of poor disease progression. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
9. An IL7RA exon 5 polymorphism is associated with impaired IL-7Rα splicing and protection against tuberculosis in Ghana
- Author
-
Lundtoft, Christian, Awuah, Anthony Afum-Adjei, Güler, Alptekin, Harling, Kirstin, Schaal, Heiner, Mayatepek, Ertan, Phillips, Richard O., Nausch, Norman, Owusu-Dabo, Ellis, and Jacobsen, Marc
- Published
- 2019
- Full Text
- View/download PDF
10. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
- Author
-
Blach, Sarah, Zeuzem, Stefan, Manns, Michael, Altraif, Ibrahim, Duberg, Ann-Sofi, Muljono, David H, Waked, Imam, Alavian, Seyed M, Lee, Mei-Hsuan, Negro, Francesco, Abaalkhail, Faisal, Abdou, Ahmed, Abdulla, Maheeba, Rached, Antoine Abou, Aho, Inka, Akarca, Ulus, Al Ghazzawi, Imad, Al Kaabi, Saad, Al Lawati, Faryal, Al Namaani, Khalid, Al Serkal, Youssif, Al-Busafi, Said A, Al-Dabal, Layla, Aleman, Soo, Alghamdi, Abdullah S, Aljumah, Abdulrahman A, Al-Romaihi, Hamad E, Andersson, Monique I, Arendt, Vic, Arkkila, Perttu, Assiri, Abdullah M, Baatarkhuu, Oidov, Bane, Abate, Ben-Ari, Ziv, Bergin, Colm, Bessone, Fernando, Bihl, Florian, Bizri, Abdul R, Blachier, Martin, Blasco, Antonio J, Mello, Carlos E Brandão, Bruggmann, Philip, Brunton, Cheryl R, Calinas, Filipe, Chan, Henry L Y, Chaudhry, Asad, Cheinquer, Hugo, Chen, Chien-Jen, Chien, Rong-Nan, Choi, Moon Seok, Christensen, Peer B, Chuang, Wan-Long, Chulanov, Vladimir, Cisneros, Laura, Clausen, Mette R, Cramp, Matthew E, Craxi, Antonio, Croes, Esther A, Dalgard, Olav, Daruich, Jorge R, de Ledinghen, Victor, Dore, Gregory J, El-Sayed, Manal H, Ergör, Gul, Esmat, Gamal, Estes, Chris, Falconer, Karolin, Farag, Elmoubashar, Ferraz, Maria L G, Ferreira, Paulo R, Flisiak, Robert, Frankova, Sona, Gamkrelidze, Ivane, Gane, Ed, García-Samaniego, Javier, Khan, Amir Ghafoor, Gountas, Ilias, Goldis, Adrian, Gottfredsson, Magnús, Grebely, Jason, Gschwantler, Michael, Pessôa, Mário Guimarães, Gunter, Jessie, Hajarizadeh, Behzad, Hajelssedig, Omer, Hamid, Saeed, Hamoudi, Waseem, Hatzakis, Angelos, Himatt, Sayed M, Hofer, Harald, Hrstic, Irena, Hui, Yee-Tak, Hunyady, Bela, Idilman, Ramazan, Jafri, Wasim, Jahis, Rohani, Janjua, Naveed Z, Jarčuška, Peter, Jeruma, Agita, Jonasson, Jón G, Kamel, Yasser, Kao, Jia-Horng, Kaymakoglu, Sabahattin, Kershenobich, David, Khamis, Jawad, Kim, Young S, Kondili, Loreta, Koutoubi, Zaher, Krajden, Mel, Krarup, Henrik, Lai, Moon-sing, Laleman, Wim, Lao, Wai-cheung, Lavanchy, Daniel, Lázaro, Pablo, Leleu, Henri, Lesi, Olufunmilayo, Lesmana, Laurentius A, Li, Michael, Liakina, Valentina, Lim, Young-Suk, Luksic, Boris, Mahomed, Adam, Maimets, Matti, Makara, Mihály, Malu, Abraham O, Marinho, Rui T, Marotta, Paul, Mauss, Stefan, Memon, Muhammad S, Correa, Maria C Mendes, Mendez-Sanchez, Nahum, Merat, Shahin, Metwally, Ammal M, Mohamed, Rosmawati, Moreno, Christophe, Mourad, Fadi H, Müllhaupt, Beat, Murphy, Kimberly, Nde, Helen, Njouom, Richard, Nonkovic, Diana, Norris, Suzanne, Obekpa, Solomon, Oguche, Stephen, Olafsson, Sigurður, Oltman, Marian, Omede, Ogu, Omuemu, Casimir, Opare-Sem, Ohene, Øvrehus, Anne L H, Owusu-Ofori, Shirley, Oyunsuren, Tsendsuren S, Papatheodoridis, George, Pasini, Ken, Peltekian, Kevork M, Phillips, Richard O, Pimenov, Nikolay, Poustchi, Hossein, Prabdial-Sing, Nishi, Qureshi, Huma, Ramji, Alnoor, Razavi-Shearer, Devin, Razavi-Shearer, Kathryn, Redae, Berhane, Reesink, Henk W, Ridruejo, Ezequiel, Robbins, Sarah, Roberts, Lewis R, Roberts, Stuart K, Rosenberg, William M, Roudot-Thoraval, Françoise, Ryder, Stephen D, Safadi, Rifaat, Sagalova, Olga, Salupere, Riina, Sanai, Faisal M, Avila, Juan F Sanchez, Saraswat, Vivek, Sarmento-Castro, Rui, Sarrazin, Christoph, Schmelzer, Jonathan D, Schréter, Ivan, Seguin-Devaux, Carole, Shah, Samir R, Sharara, Ala I, Sharma, Manik, Shevaldin, Anatoly, Shiha, Gamal E, Sievert, William, Sonderup, Mark, Souliotis, Kyriakos, Speiciene, Danute, Sperl, Jan, Stärkel, Peter, Stauber, Rudolf E, Stedman, Catherine, Struck, Daniel, Su, Tung-Hung, Sypsa, Vana, Tan, Soek-Siam, Tanaka, Junko, Thompson, Alexander J, Tolmane, Ieva, Tomasiewicz, Krzysztof, Valantinas, Jonas, Van Damme, Pierre, van der Meer, Adriaan J, van Thiel, Ingo, Van Vlierberghe, Hans, Vince, Adriana, Vogel, Wolfgang, Wedemeyer, Heiner, Weis, Nina, Wong, Vincent WS, Yaghi, Cesar, Yosry, Ayman, Yuen, Man-fung, Yunihastuti, Evy, Yusuf, Aasim, Zuckerman, Eli, and Razavi, Homie
- Published
- 2017
- Full Text
- View/download PDF
11. High prevalence of asymptomatic malaria infections in adults, Ashanti Region, Ghana, 2018
- Author
-
Heinemann, Melina, Phillips, Richard O., Vinnemeier, Christof D., Rolling, Christina C., Tannich, Egbert, and Rolling, Thierry
- Published
- 2020
- Full Text
- View/download PDF
12. High Frequency of Active HCV Infection Among Seropositive Cases in West Africa and Evidence for Multiple Transmission Pathways
- Author
-
Layden, Jennifer E., Phillips, Richard O., Owusu-Ofori, Shirley, Sarfo, Fred Stephen, Kliethermes, Stephanie, Mora, Nallely, Owusu, Dorcas, Nelson, Kenrad, Opare-Sem, Ohene, Dugas, Lara, Luke, Amy, Shoham, David, Forbi, Joseph C., Khudyakov, Yury E., and Cooper, Richard S.
- Published
- 2015
13. BCG-Vaccinated Children with Contact to Tuberculosis Patients Show Delayed Conversion of Mycobacterium tuberculosis -Specific IFN-γ Release.
- Author
-
Owusu, Dorcas O., Adankwah, Ernest, Aniagyei, Wilfred, Acheampong, Isaac, Minadzi, Difery, Yeboah, Augustine, Arthur, Joseph F., Lamptey, Millicent, Vivekanandan, Monika M., Abass, Mohammed K., Kumbel, Francis, Osei-Yeboah, Francis, Gawusu, Amidu, Batsa Debrah, Linda, Debrah, Alexander, Mayatepek, Ertan, Seyfarth, Julia, Phillips, Richard O., and Jacobsen, Marc
- Subjects
MYCOBACTERIUM tuberculosis ,TUBERCULOSIS patients ,BCG vaccines ,SYMPTOMS ,TUBERCULOSIS - Abstract
Mycobacterium (M.) bovis BCG vaccination is recommended for healthy babies after birth in several countries with a high prevalence of tuberculosis, including Ghana. Previous studies showed that BCG vaccination prevents individuals from developing severe clinical manifestations of tuberculosis, but BCG vaccination effects on the induction of IFN-γ after M. tuberculosis infection have hardly been investigated. Here, we performed IFN-γ-based T-cell assays (i.e., IFN-γ Release Assay, IGRA; T-cell activation and maturation marker assay, TAM-TB) in children who had contact with index tuberculosis patients (contacts). These contacts were classified as either being BCG vaccinated at birth (n = 77) or non-BCG-vaccinated (n = 17) and were followed up at three timepoints for a period of one year to determine immune conversion after M. tuberculosis exposure and potential infection. At baseline and month 3, BCG-vaccinated contacts had significantly lower IFN-γ levels after stimulation with M. tuberculosis-specific proteins as compared to non-BCG-vaccinated contacts. This resulted in decreased proportions of positive IGRA results (BCG-vaccinated: 60% at baseline, 57% at month 3; non-BCG-vaccinated: 77% and 88%, respectively) at month 3. However, until month 12, immune conversion in BCG-vaccinated contacts led to balanced proportions in IGRA responders and IFN-γ expression between the study groups. TAM-TB assay analyses confirmed higher proportions of IFN-γ-positive T-cells in non-BCG-vaccinated contacts. Low proportions of CD38-positive M. tuberculosis-specific T-cells were only detected in non-BCG-vaccinated contacts at baseline. These results suggest that BCG vaccination causes delayed immune conversion as well as differences in the phenotype of M. tuberculosis-specific T-cells in BCG-vaccinated contacts of tuberculosis patients. These differences are immune biomarker candidates for protection against the development of severe clinical tuberculosis manifestations. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Absence of Malaria-Associated Coagulopathy in Asymptomatic Plasmodium falciparum Infection: Results From a Cross-sectional Study in the Ashanti Region, Ghana.
- Author
-
Rolling, Christina Charlotte, Phillips, Richard O, Abass, Kabiru Mohammed, Poku, Joseph Ken Adu, Osei-Mireku, Samuel, Osei-Wusu, Bright, Thompson, William, Vinnemeier, Christof D, Huebl, Lena, Langer, Florian, Francke, Paul, Kuta, Piotr, Konrath, Sandra, Renné, Thomas, Tannich, Egbert, Rolling, Thierry, and Heinemann, Melina
- Abstract
Background Coagulopathy is common in acute symptomatic Plasmodium falciparum malaria, and the degree of coagulation abnormality correlates with parasitemia and disease severity. Chronic asymptomatic malaria has been associated with increased morbidity. However, the role of coagulation activation in asymptomatic, semi-immune individuals remains unclear. This study investigates the potential effect of asymptomatic P falciparum infection on coagulation activation in semi-immune Ghanaian adults. Methods Blood from asymptomatic Ghanaian adults with P falciparum blood stage infection detectable by polymerase chain reaction (PCR) or by both PCR and rapid diagnostic test and from noninfected individuals, was investigated. Markers of coagulation activation including global coagulation tests, D-dimer, antithrombin III, fibrinogen, and von Willebrand factor antigen were tested. Furthermore, blood count, inflammation markers, and liver and kidney function tests were assessed. Results Acquired coagulopathy was not found in asymptomatic P falciparum infection. Asymptomatic malaria was associated with significantly lower platelet counts. Systemic inflammation markers and liver and kidney function tests were not altered compared to noninfected controls. Conclusions There is no laboratory evidence for acquired coagulopathy in adults with asymptomatic P falciparum malaria in highly endemic regions. Lack of laboratory evidence for systemic inflammation and liver and kidney dysfunction indicates that asymptomatic malaria may not be associated with significant morbidity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Doxycycline Treatment of Mansonella perstans–Infected Individuals Affects Immune Cell Activation and Causes Long-term T-cell Polarization.
- Author
-
Aniagyei, Wilfred, Adjei, Jonathan Kofi, Adankwah, Ernest, Seyfarth, Julia, Mayatepek, Ertan, Berko, Daniel Antwi, Sakyi, Samuel Asamoah, Debrah, Linda Batsa, Debrah, Alexander Yaw, Hoerauf, Achim, Owusu, Dorcas O, Phillips, Richard O, and Jacobsen, Marc
- Subjects
FLOW cytometry ,IN vitro studies ,PATIENT aftercare ,DOXYCYCLINE ,TREATMENT effectiveness ,RANDOMIZED controlled trials ,FILARIASIS ,IMMUNITY ,MYCOBACTERIUM tuberculosis ,RESEARCH funding ,T cells ,PHENOTYPES - Abstract
Background Doxycycline is used for treatment of Mansonella perstans infection. Immune modulatory effects of both M. perstans and doxycycline have been described but long-term implications on host immune response are not defined. Here we determined multiple immune parameters of M. perstans– infected individuals before and after doxycycline treatment to characterize doxycycline effects on host T-cell immunity. Methods Immune characterization of doxycycline-treated M. perstans– infected individuals was performed as part of an open-label randomized clinical trial. Immune cell population phenotyping by flow cytometry and functional in vitro T-cell assays were performed at baseline, 6 months, and "long term" (18–24 months) after treatment start. Treatment efficacy, based on peripheral blood microfilaria (mf) burden, was correlated with immune parameters and effects on immune response against concomitant Mycobacterium tuberculosis infection were determined. Results Immune population phenotyping indicated changes in functional T-cell responses after doxycycline treatment. Constitutive and superantigen-induced T-cell activation and polarization towards T-helper type (T
H ) 1 phenotype at baseline declined after doxycycline treatment, whereas low proportions of TH 17 and TH 1* cells at baseline increased significantly at follow-up. In accordance, long-term decline in antigen-specific TH 1 responses against concomitant M. tuberculosis infection was seen. Notably, only TH 17 and TH 1* changes after 6 months and TH 17 at baseline were negatively correlated with M. perstans microfilaria burden or reduction, whereas long-term changes were not associated with treatment efficacy. Conclusions We found long-term immune modulatory effects of doxycycline treatment leading to decreased constitutive T-cell activation, polarization towards TH 17/TH 1*, and impaired immune response against concomitant M. tuberculosis infection. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
16. Infection with Mansonella perstans nematodes in Buruli ulcer patients, Ghana
- Author
-
Phillips, Richard O., Frimpong, Michael, Sarfo, Fred S., Kretschmer, Birte, Beissner, Marcus, Debrah, Alexander, Ampem- Amoako, Yaw, Abass, Kabiru M., Thompson, William, Duah, Mabel Sarpong, Abotsi, Justice, Adjei, Ohene, Fleischer, Bernhard, Bretzel, Gisela, Wansbrough-Jones, Mark, and Jacobsen, Marc
- Subjects
Nematoda -- Influence ,Buruli ulcer -- Complications and side effects ,Roundworm infections -- Risk factors ,Children -- Health aspects ,Health - Abstract
Buruli ulcer, caused by Mycobacterium ulcerans, is a neglected tropical disease common in rural parts of West Africa. Infection with M. ulcerans causes disfiguring skin ulcers, mainly in children. The [...]
- Published
- 2014
- Full Text
- View/download PDF
17. Rural and Semi-Urban Differences in Salt Intake, and Its Dietary Sources, in Ashanti, West Africa
- Author
-
Kerry, Sally M., Emmett, Lynsey, Micah, Frank B., Martin-Peprah, Ruby, Antwi, Sampson, Phillips, Richard O., Plange-Rhule, Jacob, Eastwood, John B., and Cappuccio, Francesco P.
- Published
- 2005
18. Cytokine‐induced transient monocyte IL‐7Ra expression and the serum milieu in tuberculosis.
- Author
-
Harelimana, Jean De Dieu, Ahor, Hubert Senanu, Benner, Bastian, Hellmuth, Sabine, Adankwah, Ernest, Minadzi, Difery, Aniagyei, Wilfred, Lamptey, Millicent Naa Koshie, Arthur, Joseph, Yeboah, Augustine, Abass, Mohammed K., Debrah, Linda Batsa, Owusu, Dorcas O., Mayatepek, Ertan, Seyfarth, Julia, Phillips, Richard O., and Jacobsen, Marc
- Subjects
TUBERCULOSIS ,TUBERCULOSIS patients ,MONOCYTES ,CELL lines ,GRANULOCYTE-macrophage colony-stimulating factor - Abstract
Bacterial components and cytokines induce IL‐7 receptor (IL‐7Rα) expression in monocytes. Aberrant low IL‐7Rα expression of monocytes has been identified as a feature of tuberculosis immunopathology. Here, we investigated the mechanisms underlying IL‐7Rα regulation of monocytes and tuberculosis serum effects on IL‐7Rα expression. Serum samples from tuberculosis patients and healthy controls, cytokine candidates, and mycobacterial components were analyzed for in vitro effects on IL‐7Rα expression of primary monocytes, monocyte‐derived macrophages (MDM), and monocyte cell lines. IL‐7Rα regulation during culture and the role of FoxO1 were characterized. In vitro activation‐induced IL‐7Rα expression in human monocytes and serum samples from tuberculosis patients boosted IL‐7Rα expression. Although pathognomonic tuberculosis cytokines were not associated with serum effects, we identified cytokines (i.e., GM‐CSF, IL‐1β, TNF‐α, IFN‐γ) that induced IL‐7Rα expression in monocytes and/or MDM comparable to mycobacterial components. Blocking of cytokine subsets (i.e., IL‐1β/TNF‐α in monocytes, GM‐CSF in MDM) largely diminished IL‐7Rα expression induced by mycobacterial components. Finally, we showed that in vitro‐induced IL‐7Rα expression was transient and dependent on constitutive FoxO1 expression in primary monocytes and monocyte cell lines. This study demonstrated the crucial roles of cytokines and constitutive FoxO1 expression for transient IL‐7Rα expression in monocytes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. T-Cell Responses Against Mycobacterium ulcerans and Mycobacterium tuberculosis Protein Extracts Identify Children With Buruli Ulcer Disease.
- Author
-
Jacobsen, Marc, Adjei, Jonathan Kofi, Aniagyei, Wilfred, Adankwah, Ernest, Seyfarth, Julia, Mayatepek, Ertan, Antwi-Berko, Daniel, Sakyi, Samuel Asamoah, Debrah, Alexander Y, Debrah, Linda Batsa, Owusu, Dorcas O, and Phillips, Richard O
- Subjects
PROTEINS ,DISEASE progression ,MYCOBACTERIUM tuberculosis ,BCG vaccines ,MIXED infections ,ENZYME-linked immunosorbent assay ,T cells ,GRAM-positive bacteria ,BURULI ulcer ,CHILDREN - Abstract
Immune-based diagnosis of Buruli ulcer disease (BUD) in children is difficult due to cross-reactivity between mycobacteria. We found that T-cell IFNγ/TNFα responses against Mycobacterium (M.) ulcerans and M. tuberculosis (PPD
Mulc , PPDMtub ) were different between children with BUD (n = 27) and TB (n = 20) but only ratios (PPDMtub /PPDMulc ) discriminated the study groups efficiently. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
20. Performance of COVID-19 associated symptoms and temperature checking as a screening tool for SARS-CoV-2 infection.
- Author
-
Nuertey, Benjamin Demah, Ekremet, Kwame, Haidallah, Abdul-Rashid, Mumuni, Kareem, Addai, Joyce, Attibu, Rosemary Ivy E., Damah, Michael C., Duorinaa, Elvis, Seidu, Anwar Sadat, Adongo, Victor C., Adatsi, Richard Kujo, Suri, Hisyovi Caedenas, Komei, Abass Abdul-Karim, Abubakari, Braimah Baba, Weyori, Enoch, Allegye-Cudjoe, Emmanuel, Sylverken, Augustina, Owusu, Michael, and Phillips, Richard O.
- Subjects
COVID-19 ,SARS-CoV-2 ,SYMPTOMS ,PUBLIC spaces ,INFRARED thermometers ,SOCIAL distancing - Abstract
Introduction: Coronavirus disease-19 (COVID-19), which started in late December, 2019, has spread to affect 216 countries and territories around the world. Globally, the number of cases of SARS-CoV-2 infection has been growing exponentially. There is pressure on countries to flatten the curves and break transmission. Most countries are practicing partial or total lockdown, vaccination, massive education on hygiene, social distancing, isolation of cases, quarantine of exposed and various screening approaches such as temperature and symptom-based screening to break the transmission. Some studies outside Africa have found the screening for fever using non-contact thermometers to lack good sensitivity for detecting SARS-CoV-2 infection. The aim of this study was to determine the usefulness of clinical symptoms in accurately predicting a final diagnosis of COVID-19 disease in the Ghanaian setting. Method: The study analysed screening and test data of COVID-19 suspected, probable and contacts for the months of March to August 2020. A total of 1,986 participants presenting to Tamale Teaching hospital were included in the study. Logistic regression and receiver operator characteristics (ROC) analysis were carried out. Results: Overall SARS-CoV-2 positivity rate was 16.8%. Those with symptoms had significantly higher positivity rate (21.6%) compared with asymptomatic (17.0%) [chi-squared 15.5, p-value, <0.001]. Patients that were positive for SARS-CoV-2 were 5.9 [3.9–8.8] times more likely to have loss of sense of smell and 5.9 [3.8–9.3] times more likely to having loss of sense of taste. Using history of fever as a screening tool correctly picked up only 14.8% of all true positives of SARS-CoV-2 infection and failed to pick up 86.2% of positive cases. Using cough alone would detect 22.4% and miss 87.6%. Non-contact thermometer used alone, as a screening tool for COVID-19 at a cut-off of 37.8 would only pick 4.8% of positive SARS-CoV-2 infected patients. Conclusion: The use of fever alone or other symptoms individually [or in combination] as a screening tool for SARS-CoV-2 infection is not worthwhile based on ROC analysis. Use of temperature check as a COVID-19 screening tool to allow people into public space irrespective of the temperature cut-off is of little benefit in diagnosing infected persons. We recommend the use of facemask, hand hygiene, social distancing as effective means of preventing infection. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Emerging aspects of Buruli ulcer
- Author
-
Thangaraj, Harry S, Phillips, Richard O, Evans, Mark RW, and Wansbrough-Jones, Mark H
- Published
- 2003
22. Mapping suitability for Buruli ulcer at fine spatial scales across Africa: A modelling study.
- Author
-
Simpson, Hope, Tabah, Earnest Njih, Phillips, Richard O., Frimpong, Michael, Maman, Issaka, Ampadu, Edwin, Timothy, Joseph, Saunderson, Paul, Pullan, Rachel L., and Cano, Jorge
- Subjects
BURULI ulcer ,RURAL poor ,ECOLOGICAL niche ,MACHINE learning ,TROPICAL medicine ,STATISTICAL models - Abstract
Buruli ulcer (BU) is a disabling and stigmatising neglected tropical disease (NTD). Its distribution and burden are unknown because of underdiagnosis and underreporting. It is caused by Mycobacterium ulcerans, an environmental pathogen whose environmental niche and transmission routes are not fully understood. The main control strategy is active surveillance to promote early treatment and thus limit morbidity, but these activities are mostly restricted to well-known endemic areas. A better understanding of environmental suitability for the bacterium and disease could inform targeted surveillance, and advance understanding of the ecology and burden of BU. We used previously compiled point-level datasets of BU and M. ulcerans occurrence, evidence for BU occurrence within national and sub-national areas, and a suite of relevant environmental covariates in a distribution modelling framework. We fitted relationships between BU and M. ulcerans occurrence and environmental predictors by applying regression and machine learning based algorithms, combined in an ensemble model to characterise the optimal ecological niche for the disease and bacterium across Africa at a resolution of 5km x 5km. Proximity to waterbodies was the strongest predictor of suitability for BU, followed potential evapotranspiration. The strongest predictors of suitability for M. ulcerans were deforestation and potential evapotranspiration. We identified patchy foci of suitability throughout West and Central Africa, including areas with no previous evidence of the disease. Predicted suitability for M. ulcerans was wider but overlapping with that of BU. The estimated population living in areas predicted suitable for the bacterium and disease was 46.1 million. These maps could be used to inform burden estimations and case searches which would generate a more complete understanding of the spatial distribution of BU in Africa, and may guide control programmes to identify cases beyond the well-known endemic areas. Author summary: Like many neglected tropical diseases primarily affecting the rural poor, Buruli ulcer (BU) is under-detected and under-reported within routine health information systems. As such, the burden and distribution are not fully known, impeding appropriate targeting of health resources, control, and care for people affected. Having previously evaluated and mapped the existing evidence for BU and its causative agent M. ulcerans, we concluded that the disease was likely to occur beyond the range of known endemic areas. However, we were left with the question of where exactly these undetected cases might be occurring. Answering this question required a more fine-scale approach: BU is highly focal, presumably due to local variation in the environmental factors which determine suitability for M. ulcerans survival and transmission to humans. We used the compiled evidence and geographical datasets to build statistical models representing the relationship between environmental factors and previously reported cases. This allowed us to define the ecological niche of BU, and subsequently to identify areas across Africa where this niche was met, providing suitable conditions for the disease. We constructed separate models of suitability for M. ulcerans, using locations where its DNA had been detected in environmental sources. Unsurprisingly, suitability for M. ulcerans was predicted to be wider than, but geographically overlapping with that for BU. This implies that beyond the conditions necessary for survival of the bacterium, additional factors are required for transmission to humans. The high-resolution suitability maps we present are intended to guide case search activities which may identify endemic areas beyond the known endemic range. Data on the true prevalence of BU from targeted case searches within predicted-suitable areas will also allow us to validate and refine the models, and potentially to predict the probability of cases occurring within predicted suitable areas. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Interleukin-6 and Mycobacterium tuberculosis dormancy antigens improve diagnosis of tuberculosis.
- Author
-
Adankwah, Ernest, Nausch, Norman, Minadzi, Difery, Abass, Mohammed K., Franken, Kees L.M.C., Ottenhoff, Tom H.M., Mayatepek, Ertan, Phillips, Richard O., and Jacobsen, Marc
- Abstract
Objectives: IFNγ-release assays (IGRAs) used for diagnosis of Mycobacterium (M.) tuberculosis infection have limited sensitivity. Alternative cytokines and M. tuberculosis latency-associated antigens may improve immune-based tests.Methods: Multiplex cytokine analyses was done in culture supernatants after 6-day in vitro restimulation with M. tuberculosis IGRA and latency-associated antigens (i.e. Rv2628, Rv1733) in tuberculosis patients (n = 22) and asymptomatic contacts (AC)s (n = 20) from Ghana.Results: Four cytokines (i.e. IFNγ, IP-10, IL-22 and IL-6) were significantly increased after IGRA-antigen specific restimulation. IFNγ, IP-10, and IL-22 correlated positively and showed no differences between the study groups whereas IGRA-antigen induced IL-6 was significantly higher in tuberculosis patients. Using adjusted IGRA criteria, IL-6 showed the highest sensitivity for detection of tuberculosis patients (91%) and ACs (85%) as compared to IFNγ, IP-10, and IL-22. Rv2628 and Rv1733 restimulation induced significantly higher IFNγ, IP-10, and IL-22 concentrations in ACs. Combined antigen/cytokine analyses identified study group specific patterns and a combination of Rv2628/Rv1733 induced IFNγ with IGRA-antigen induced IL-6 was optimal for classification of tuberculosis patients and ACs (AUC: 0.92, p<0.0001).Conclusions: We demonstrate the potency of alternative cytokines, especially IL-6, and latency-associated antigens Rv1733/Rv2628 to improve detection of M. tuberculosis infection and to classify tuberculosis patients and healthy contacts. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
24. Towards a comprehensive research and development plan to support the control, elimination and eradication of neglected tropical diseases.
- Author
-
Mabey, David, Agler, Ellen, Amuasi, John H, Hernandez, Leda, Hollingsworth, T Déirdre, Hotez, Peter J, Lammie, Patrick J, Malecela, Mwelecele N, Matendechero, Sultani H, Ottesen, Eric, Phillips, Richard O, Reeder, John C, Szwarcwald, Célia Landmann, Shott, Joseph P, Solomon, Anthony W, Steer, Andrew, and Swaminathan, Soumya
- Subjects
TROPICAL medicine ,RESEARCH & development ,HEALTH programs ,WORLD health - Abstract
To maximise the likelihood of success, global health programmes need repeated, honest appraisal of their own weaknesses, with research undertaken to address any identified gaps. There is still much to be learned to optimise work against neglected tropical diseases. To facilitate that learning, a comprehensive research and development plan is required. Here, we discuss how such a plan might be developed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Diagnostics for COVID-19: A case for field-deployable, rapid molecular tests for community surveillance.
- Author
-
Frimpong, Michael, Amoako, Yaw A., Anim, Kwadwo B., Ahor, Hubert S., Yeboah, Richmond, Arthur, Joshua, Dakorah, Justin S., Gborgblovor, Delphine, Akrofi, Samuel, Sekyi-Djan, Phyllis, Owusu, Michael, Sylverken, Augustina A., Binger, Tabea, and Phillips, Richard O.
- Subjects
COVID-19 ,SARS-CoV-2 ,COVID-19 pandemic ,CONTACT tracing ,VIRAL transmission - Abstract
Across the globe, the outbreak of the COVID-19 pandemic is causing distress with governments doing everything in their power to contain the spread of the novel coronavirus (SARS-CoV-2) to prevent morbidity and mortality. Actions are being implemented to keep health care systems from being overstretched and to curb the outbreak. Any policy responses aimed at slowing down the spread of the virus and mitigating its immediate effects on health care systems require a firm basis of information about the absolute number of currently infected people, growth rates, and locations/hotspots of infections. The only way to obtain this base of information is by conducting numerous tests in a targeted way. Currently, in Ghana, there is a centralized testing approach, that takes 4-5 days for samples to be shipped and tested at central reference laboratories with results communicated to the district, regional and national stakeholders. This delay in diagnosis increases the risk of ongoing transmission in communities and vulnerable institutions. We have validated, evaluated and deployed an innovative diagnostic tool on a mobile laboratory platform to accelerate the COVID-19 testing. A preliminary result of 74 samples from COVID-19 suspected cases has a positivity rate of 12% with a turn-around time of fewer than 3 hours from sample taking to reporting of results, significantly reducing the waiting time from days to hours, enabling expedient response by the health system for contact tracing to reduce transmission and additionally improving case management. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. Profile and outcomes of hospitalized patients with COVID-19 at a tertiary institution hospital in Ghana.
- Author
-
Ayisi-Boateng, Nana K., Owusu, Michael, Tawiah, Phyllis, Ampah, Brenda A., Sylverken, Augustina A., Wusu-Ansah, Osei K., Sarfo, Fred S., and Phillips, Richard O.
- Subjects
COVID-19 ,HOSPITAL patients ,COVID-19 treatment ,SYSTOLIC blood pressure ,HYPERTENSION - Abstract
Background: In high-income countries, mortality related to hospitalized patients with the Coronavirus disease 2019 (COVID-19) is approximately 4-5%. However, data on COVID-19 admissions from sub-Saharan Africa are scanty. Objective: To describe the clinical profile and determinants of outcomes of patients with confirmed COVID-19 admitted at a hospital in Ghana. Methods: A prospective study involving 25 patients with real time polymerase chain reaction confirmed COVID-19 admitted to the treatment centre of the University Hospital, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana from 1st June to 27th July, 2020. They were managed and followed up for outcomes. Data were analysed descriptively, and predictors of mortality assessed using a multivariate logistic regression modelling. Results: The mean age of the patients was 59.3 ± 20.6 years, and 14 (56%) were males. The main symptoms at presentation were breathlessness (68%) followed by fever (56%). The cases were categorized as mild (6), moderate (6), severe (10) and critical (3). Hypertension was the commonest comorbidity present in 72% of patients. Medications used in patient management included dexamethasone (68%), azithromycin (96%), and hydroxychloroquine (4%). Five of 25 cases died (Case fatality ratio 20%). Increasing age and high systolic blood pressure were associated with mortality. Conclusion: Case fatality in this sample of hospitalized COVID-19 patients was high. Thorough clinical assessment, severity stratification, aggressive management of underlying co-morbidities and standardized protocols incountry might improve outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. Barriers to Buruli ulcer treatment completion in the Ashanti and Central Regions, Ghana.
- Author
-
Collinson, Shelui, Frimpong, Venus N. B., Agbavor, Bernadette, Montgomery, Bethany, Oppong, Michael, Frimpong, Michael, Amoako, Yaw A., Marks, Michael, and Phillips, Richard O.
- Subjects
MEDICAL records ,SECONDARY analysis ,LOGISTIC regression analysis ,WOUND care - Abstract
Background: Buruli ulcer is a chronic ulcerating skin condition, with the highest burden found in Central and West Africa where it disproportionately affects the most vulnerable populations. Treatment is demanding, comprising eight-weeks of daily antibiotics, regular wound care and possible surgical intervention. Treatment completion is key to optimising outcomes, however the degree of and barriers to this are not well understood. Recent change from injectable treatment (SR8) to oral treatment (CR8) has made it feasible to further decentralise care, potentially improving treatment access and completion. However, the impact of this and of other demographic and clinical influences on treatment completion must be explored first to ensure appropriate models of care are developed. Methodology/Principal findings: A retrospective clinical notes review and secondary data analysis of records from patients diagnosed between 1 January 2006–31 December 2018 at four district hospital clinics in the Ashanti and Central Regions, Ghana. Univariable analyses and multivariable logistic regression were performed to assess the association between explanatory variables and treatment completion. There were 931 patient episodes across the four clinics with overall treatment completion of 84.4%. CR8 was associated with higher treatment completion compared to SR8 (OR 4.1, P = 0.001). There was no statistically significant association found between distance from patient residence to clinic and treatment completion. Conclusions/Significance: Improved treatment completion with CR8 supports its use as first line therapy and may enable decentralisation to fully community-based care. We did not find an association between distance to care and treatment completion, though analyses were limited by data availability. However, we did find evidence that distance to care continues to be associated with more severe forms of disease, which may reflect the higher costs of accessing care and lower awareness of the condition the further a patient lives. Decentralised care must therefore also continue to support community engagement and active outreach to identify cases early. Author summary: Buruli ulcer (BU) is a chronic ulcerating tropical skin disease known to particularly affect vulnerable populations. Without early detection and effective treatment it can lead to disfigurement, disability and stigma. In order to improve outcomes, we need to understand what factors prevent patients from accessing and completing treatment, however these factors are often not well understood. Factors considered to potentially affect treatment completion include access to care and type of treatment. In this study we analysed data available from clinical records of patients treated in Ghana to identify whether type of treatment and common patient characteristics were associated with treatment completion. We found that treatment completion was higher in patients who took a newly introduced oral treatment compared to those who took the traditional injectable treatment. We did not find a difference in treatment completion between patients living close to the clinic and those living further away, however we found that those living further were more likely to present with more advanced disease. The results from this study suggest that management for patients living far from care needs to be improved. The newly recommended oral treatment makes it feasible to provide care away from health centres and the improved treatment completion seen in this study supports its use. However, further research should be conducted to determine how fully community based care can best be provided. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.
- Author
-
Phillips, Richard O, Robert, Jérôme, Abass, Kabiru Mohamed, Thompson, William, Sarfo, Fred Stephen, Wilson, Tuah, Sarpong, Godfred, Gateau, Thierry, Chauty, Annick, Omollo, Raymond, Ochieng Otieno, Michael, Egondi, Thaddaeus W, Ampadu, Edwin O, Agossadou, Didier, Marion, Estelle, Ganlonon, Line, Wansbrough-Jones, Mark, Grosset, Jacques, Macdonald, John M, and Treadwell, Terry
- Subjects
- *
BURULI ulcer , *STREPTOMYCIN , *RIFAMPIN , *SURGICAL excision , *MYCOBACTERIAL diseases , *SKIN grafting , *WOUND healing , *RESEARCH , *COMBINATION drug therapy , *ORAL drug administration , *RESEARCH methodology , *CLARITHROMYCIN , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *RANDOMIZED controlled trials , *CONTROLLED release preparations , *RESEARCH funding , *STATISTICAL sampling , *ANTIBIOTICS - Abstract
Background: Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia. Standard antimicrobial treatment with oral rifampicin 10 mg/kg plus intramuscular streptomycin 15 mg/kg once daily for 8 weeks (RS8) is highly effective, but streptomycin injections are painful and potentially harmful. We aimed to compare the efficacy and tolerability of fully oral rifampicin 10 mg/kg plus clarithromycin 15 mg/kg extended release once daily for 8 weeks (RC8) with that of RS8 for treatment of early Buruli ulcer lesions.Methods: We did an open-label, non-inferiority, randomised (1:1 with blocks of six), multicentre, phase 3 clinical trial comparing fully oral RC8 with RS8 in patients with early, limited Buruli ulcer lesions. There were four trial sites in hospitals in Ghana (Agogo, Tepa, Nkawie, Dunkwa) and one in Benin (Pobè). Participants were included if they were aged 5 years or older and had typical Buruli ulcer with no more than one lesion (caterories I and II) no larger than 10 cm in diameter. The trial was open label, and neither the investigators who took measurements of the lesions nor the attending doctors were masked to treatment assignment. The primary clinical endpoint was lesion healing (ie, full epithelialisation or stable scar) without recurrence at 52 weeks after start of antimicrobial therapy. The primary endpoint and safety were assessed in the intention-to-treat population. A sample size of 332 participants was calculated to detect inferiority of RC8 by a margin of 12%. This study was registered with ClinicalTrials.gov, NCT01659437.Findings: Between Jan 1, 2013, and Dec 31, 2017, participants were recruited to the trial. We stopped recruitment after 310 participants. Median age of participants was 14 years (IQR 10-29) and 153 (52%) were female. 297 patients had PCR-confirmed Buruli ulcer; 151 (51%) were assigned to RS8 treatment, and 146 (49%) received oral RC8 treatment. In the RS8 group, lesions healed in 144 (95%, 95% CI 91 to 98) of 151 patients, whereas lesions healed in 140 (96%, 91 to 99) of 146 patients in the RC8 group. The difference in proportion, -0·5% (-5·2 to 4·2), was not significantly greater than zero (p=0·59), showing that RC8 treatment is non-inferior to RS8 treatment for lesion healing at 52 weeks. Treatment-related adverse events were recorded in 20 (13%) patients receiving RS8 and in nine (7%) patients receiving RC8. Most adverse events were grade 1-2, but one (1%) patient receiving RS8 developed serious ototoxicity and ended treatment after 6 weeks. No patients needed surgical resection. Four patients (two in each study group) had skin grafts.Interpretation: Fully oral RC8 regimen was non-inferior to RS8 for treatment of early, limited Buruli ulcer and was associated with fewer adverse events. Therefore, we propose that fully oral RC8 should be the preferred therapy for early, limited lesions of Buruli ulcer.Funding: WHO with additional support from MAP International, American Leprosy Missions, Fondation Raoul Follereau France, Buruli ulcer Groningen Foundation, Sanofi-Pasteur, and BuruliVac. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
29. Pharmacologic management of Mycobacterium ulcerans infection.
- Author
-
Van Der Werf, Tjip S, Barogui, Yves T, Converse, Paul J, Phillips, Richard O, and Stienstra, Ymkje
- Subjects
MYCOBACTERIAL diseases ,EXOTOXIN ,CLARITHROMYCIN ,BURULI ulcer ,PATHOLOGY ,STREPTOMYCIN ,MOXIFLOXACIN - Abstract
Pharmacological treatment of Buruli ulcer (Mycobacterium ulcerans infection; BU) is highly effective, as shown in two randomized trials in Africa. We review BU drug treatment – in vitro, in vivo and clinical trials (PubMed: '(Buruli OR (Mycobacterium AND ulcerans)) AND (treatment OR therapy).' We also highlight the pathogenesis of M. ulcerans infection that is dominated by mycolactone, a secreted exotoxin, that causes skin and soft tissue necrosis, and impaired immune response and tissue repair. Healing is slow, due to the delayed wash-out of mycolactone. An array of repurposed tuberculosis and leprosy drugs appears effective in vitro and in animal models. In clinical trials and observational studies, only rifamycins (notably, rifampicin), macrolides (notably, clarithromycin), aminoglycosides (notably, streptomycin) and fluoroquinolones (notably, moxifloxacin, and ciprofloxacin) have been tested. A combination of rifampicin and clarithromycin is highly effective but lesions still take a long time to heal. Novel drugs like telacebec have the potential to reduce treatment duration but this drug may remain unaffordable in low-resourced settings. Research should address ulcer treatment in general; essays to measure mycolactone over time hold promise to use as a readout for studies to compare drug treatment schedules for larger lesions of Buruli ulcer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
30. Paradoxical reactions in Buruli ulcer after initiation of antibiotic therapy: Relationship to bacterial load.
- Author
-
Frimpong, Michael, Agbavor, Bernadette, Duah, Mabel Sarpong, Loglo, Aloysius, Sarpong, Francisca N., Boakye-Appiah, Justice, Abass, Kabiru M., Dongyele, Mathias, Amofa, George, Tuah, Wilson, Frempong, Margaret, Amoako, Yaw A., Wansbrough-Jones, Mark, and Phillips, Richard O.
- Subjects
BURULI ulcer ,HEALING ,ANTIBIOTICS ,NUCLEIC acids ,RIBOSOMAL RNA - Abstract
Background: We investigated the relationship between bacterial load in Buruli ulcer (BU) lesions and the development of paradoxical reaction following initiation of antibiotic treatment. Methods: This was a longitudinal study involving BU patients from June 2013 to June 2017. Fine needle aspirates (FNA) and swab samples were obtained to establish the diagnosis of BU by PCR. Additional samples were obtained at baseline, during and after treatment (if the lesion had not healed) for microscopy, culture and combined 16S rRNA reverse transcriptase/ IS2404 qPCR assay. Patients were followed up at regular intervals until complete healing. Results: Forty-seven of 354 patients (13%) with PCR confirmed BU had a PR, occurring between 2 and 42 (median 6) weeks after treatment initiation. The bacterial load, the proportion of patients with positive M. ulcerans culture (15/34 (44%) vs 29/119 (24%), p = 0.025) and the proportion with positive microscopy results (19/31 (61%) vs 28/90 (31%), p = 0.003) before initiation of treatment were significantly higher in the PR compared to the no PR group. Plaques (OR 5.12; 95% CI 2.26–11.61; p<0.001), oedematous (OR 4.23; 95% CI 1.43–12.5; p = 0.009) and category II lesions (OR 2.26; 95% CI 1.14–4.48; p = 0.02) were strongly associated with the occurrence of PR. The median time to complete healing (28 vs 13 weeks, p <0.001) was significantly longer in the PR group. Conclusions: Buruli ulcer patients who develop PR are characterized by high bacterial load in lesion samples taken at baseline and a higher rate of positive M. ulcerans culture. Occurrence of a PR was associated with delayed healing. Trial registration: ClinicalTrials.gov . [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
31. The Efficacy of Doxycycline Treatment on Mansonella perstans Infection: An Open-Label, Randomized Trial in Ghana.
- Author
-
Debrah, Linda Batsa, Phillips, Richard O., Pfarr, Kenneth, Klarmann-Schulz, Ute, Opoku, Vera Serwaa, Nausch, Norman, Owusu, Wellington, Mubarik, Yusif, Sander, Anna-Lena, Lämmer, Christine, Ritter, Manuel, Layland, Laura E., Jacobsen, Marc, Debrah, Alexander Yaw, and Hoerauf, Achim
- Published
- 2019
- Full Text
- View/download PDF
32. The paediatric participation scale measuring participation restrictions among former Buruli Ulcer patients under the age of 15 in Ghana and Benin: Development and first validation results.
- Author
-
Beeres, Dorien T., Horstman, Jacolien, van der Tak, Pierre, Phillips, Richard O., Abass, Kabiru M., van der Werf, Tjip, Johnson, Roch C., Sopoh, Ghislain E., de Zeeuw, Janine, Dijkstra, Pieter U., Barogui, Yves T., and Stienstra, Ymkje
- Subjects
BURULI ulcer ,PARTICIPATION - Abstract
Background: Buruli Ulcer (BU) is a neglected tropical disease caused by Mycobacterium ulcerans. Former BU patients may experience participation restrictions due to physical limitations, stigmatization and other social factors. A scale that measures participation restrictions among children, who represent almost half of the affected population, has not been developed yet. Here, we present the development of a scale that measures participation restrictions in former BU paediatric patients, the psychometric properties of this scale and the scales’ results. Methods: Items were selected and a scale was developed based on interviews with health care workers and former BU patients in and around the BU treatment centre in Lalo, Benin. Construct validity was tested using six a priori formulated hypotheses. Former BU patients under 15 years of age who received treatment in one of the BU treatment centres in Ghana and Benin between 2007–2012 were interviewed. Results: A feasible 16-item scale that measures the concept of participation among children under 15 years of age was developed. In total, 109 (Ghana) and 90 (Benin) former BU patients were interviewed between 2012–2017. Five construct validity hypotheses were confirmed of which 2 hypotheses related to associations with existing questionnaires were statistically significant (p<0.05). In Ghana 77% of the former patients had a Paediatric Participation (PP) scale score of 0 compared to 22% in Benin. More severe lesions related to BU were seen in Benin. Most of the reported participation problems were related to sports, mainly in playing games with others, going to the playfield and doing sports at school. Conclusion: The preliminary results of the PP-scale validation are promising but further validation is needed. The developed PP-scale may be valid for use in patients with more severe BU lesions. This is the first research to confirm that former BU patients under 15-year face participation restrictions in important aspects of their lives. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
33. Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring.
- Author
-
Villa, Giovanni, Ruggiero, Alessandra, Beloukas, Apostolos, Geretti, Anna Maria, Phillips, Richard O, Smith, Colette, Stockdale, Alexander J, Appiah, Lambert T, Sarfo, Fred S, and Chadwick, David
- Subjects
DRUG resistance ,TENOFOVIR ,BISOPROLOL ,DRUG monitoring ,COMPARATIVE studies ,DRUG resistance in microorganisms ,HETEROCYCLIC compounds ,HIV ,HIV infections ,RESEARCH methodology ,MEDICAL cooperation ,GENETIC mutation ,RESEARCH ,RESEARCH funding ,TIME ,VIRAL load ,EVALUATION research ,HIGHLY active antiretroviral therapy ,TREATMENT effectiveness ,VIREMIA ,LAMIVUDINE ,ANTI-HIV agents ,REVERSE transcriptase inhibitors - Abstract
Objectives: The resistance profiles of patients receiving long-term ART in sub-Saharan Africa have been poorly described. This study obtained a sensitive assessment of the resistance patterns associated with long-term tenofovir-based ART in a programmatic setting where virological monitoring is yet to become part of routine care.Methods: We studied subjects who, after a median of 4.2 years of ART, replaced zidovudine or stavudine with tenofovir disoproxil fumarate while continuing lamivudine and an NNRTI. Using deep sequencing, resistance-associated mutations (RAMs) were detected in stored samples collected at tenofovir introduction (T0) and after a median of 4.0 years (T1).Results: At T0, 19/87 (21.8%) subjects showed a detectable viral load and 8/87 (9.2%) had one or more major NNRTI RAMs, whereas 82/87 (94.3%) retained full tenofovir susceptibility. At T1, 79/87 (90.8%) subjects remained on NNRTI-based ART, 5/87 (5.7%) had introduced lopinavir/ritonavir due to immunological failure, and 3/87 (3.4%) had interrupted ART. Whilst 68/87 (78.2%) subjects maintained or achieved virological suppression between T0 and T1, a detectable viral load with NNRTI RAMs at T0 predicted lack of virological suppression at T1. Each treatment interruption, usually reflecting unavailability of the dispensary, doubled the risk of T1 viraemia. Tenofovir, lamivudine and efavirenz selected for K65R, K70E/T, L74I/V and Y115F, alongside M184V and multiple NNRTI RAMs; this resistance profile was accompanied by high viral loads and low CD4 cell counts.Conclusions: Viraemia on tenofovir, lamivudine and efavirenz led to complex resistance patterns with implications for continued drug activity and risk of onward transmission. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
34. Prevention of hypertension and stroke in Africa
- Author
-
Cappuccio, Francesco P, Plange-Rhule, Jacob, Phillips, Richard O, Eastwood, John B, and Yikona, Joseph
- Subjects
Hypertension -- Prevention ,Stroke (Disease) -- Prevention ,Sub-Saharan Africa -- Health aspects - Published
- 2000
35. Type‐1 diabetes onset age and sex differences between Ghanaian and German urban populations.
- Author
-
Seyfarth, Julia, Sarfo‐Kantanka, Osei, Rosenbauer, Joachim, Phillips, Richard O., and Jacobsen, Marc
- Subjects
CITY dwellers ,AGE of onset ,AGE differences ,TYPE 1 diabetes - Abstract
In a retrospective hospital-based study, we determined onset age and sex of T1D patients from Kumasi/Ghana and NRW/Germany. GLO:55QH/01dec19:jdb12978-fig-0001.jpg PHOTO (COLOR): Onset age distributions and localization for T1D patients from NRW/Germany and Kumasi/Ghana. The relatively late T1D onset seen in the urban T1D cohort from Ghana may reflect differences in T1D susceptibility gene distribution between both populations as well as distinct prevalent infections in sub-Saharan Ghana. [Extracted from the article]
- Published
- 2019
- Full Text
- View/download PDF
36. IFN-γ and IL-5 whole blood response directed against mycolactone polyketide synthase domains in patients with Mycobacterium ulcerans infection.
- Author
-
Loglo, Aloysius D., Frimpong, Michael, Duah, Mabel Sarpong, Sarfo, Fred, Sarpong, Francisca N., Agbavor, Bernadette, Boakye-Appiah, Justice K., Abass, Kabiru M., Dongyele, Mathias, Frempong, Margaret, Pidot, Sacha, Wansbrough-Jones, Mark, Stinear, Timothy P., Roupie, Virginie, Huygen, Kris, and Phillips, Richard O.
- Subjects
MYCOBACTERIAL diseases ,ACYL carrier protein ,POLYKETIDE synthases ,BURULI ulcer ,SOFT tissue infections ,ENZYME-linked immunosorbent assay - Abstract
Background: Buruli ulcer is a disease of the skin and soft tissues caused by infection with a slow growing pathogen, Mycobacterium ulcerans. A vaccine for this disease is not available but M. ulcerans possesses a giant plasmid pMUM001 that harbours the polyketide synthase (PKS) genes encoding a multi-enzyme complex needed for the production of its unique lipid toxin called mycolactone, which is central to the pathogenesis of Buruli ulcer. We have studied the immunogenicity of enzymatic domains in humans with M. ulcerans disease, their contacts, as well as non-endemic areas controls. Methods: Between March 2013 and August 2015, heparinized whole blood was obtained from patients confirmed with Buruli ulcer. The blood samples were diluted 1 in 10 in Roswell Park Memorial Institute (RPMI) medium and incubated for 5 days with recombinant mycolactone PKS domains and mycolyltransferase antigen 85A (Ag85A). Blood samples were obtained before and at completion of antibiotic treatment for 8 weeks and again 8 weeks after completion of treatment. Supernatants were assayed for interferon-γ (IFN-γ) and interleukin-5 (IL-5) by enzyme-linked immunosorbent assay. Responses were compared with those of contacts and non-endemic controls. Results: More than 80% of patients and contacts from endemic areas produced IFN-γ in response to all the antigens except acyl carrier protein type 3 (ACP3) to which only 47% of active Buruli ulcer cases and 71% of contacts responded. The highest proportion of responders in cases and contacts was to load module ketosynthase domain (Ksalt) (100%) and enoylreductase (100%). Lower IL-5 responses were induced in a smaller proportion of patients ranging from 54% after ketoreductase type B stimulation to only 21% with ketosynthase type C (KS C). Among endemic area contacts, the, highest proportion was 73% responding to KS C and the lowest was 40% responding to acyltransferase with acetate specificity type 2. Contacts of Buruli ulcer patients produced significantly higher IFN-γ and IL-5 responses compared with those of patients to PKS domain antigens and to mycolyltransferase Ag85A of M. ulcerans. There was low or no response to all the antigens in non-endemic areas controls. IFN-γ and IL-5 responses of patients improved after treatment when compared to baseline results. Discussion: The major response to PKS antigen stimulation was IFN-γ and the strongest responses were observed in healthy contacts of patients living in areas endemic for Buruli ulcer. Patients elicited lower responses than healthy contacts, possibly due to the immunosuppressive effect of mycolactone, but the responses were enhanced after antibiotic treatment. A vaccine made up of the most immunogenic PKS domains combined with the mycolyltransferase Ag85A warrants further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
37. Analysis of Mycobacterium ulcerans-specific T-cell cytokines for diagnosis of Buruli ulcer disease and as potential indicator for disease progression.
- Author
-
Nausch, Norman, Antwi-Berko, Daniel, Mubarik, Yusif, Abass, Kabiru Mohammed, Owusu, Wellington, Owusu-Dabo, Ellis, Debrah, Linda Batsa, Debrah, Alexander Yaw, Jacobsen, Marc, and Phillips, Richard O.
- Subjects
PHYSIOLOGICAL effects of cytokines ,BURULI ulcer ,DIAGNOSIS of bacterial diseases ,DISEASE progression ,DISEASE management ,DIAGNOSIS - Abstract
Background: Buruli ulcer disease (BUD), caused by Mycobacterium (M.) ulcerans, is the third most common mycobacterial disease after tuberculosis and leprosy. BUD causes necrotic skin lesions and is a significant problem for health care in the affected countries. As for other mycobacterial infections, T cell mediated immune responses are important for protection and recovery during treatment, but detailed studies investigating these immune responses in BUD patients are scarce. In this study, we aimed to characterise M. ulcerans-specific CD4+ T cell responses in BUD patients and to analyse specific cytokine-producing T cells in the context of disease severity and progression. Methodology/Principal findings: For this case-control study, whole blood samples of BUD patients (N = 36, 1.5–17 years of age) and healthy contacts (N = 22, 3–15 years of age) were stimulated with antigen prepared from M. ulcerans and CD4+ T cells were analysed for the expression of TNFα, IFNγ and CD40L by flow cytometry. The proportions and profile of cytokine producing CD4+ T cells was compared between the two study groups and correlated with disease progression and severity. Proportions of cytokine double-positive IFNγ+TNFα+, TNFα+CD40L+, IFNγ+CD40L+ (p = 0.014, p = 0.010, p = 0.002, respectively) and triple positive IFNγ+TNFα+CD40L+ (p = 0.010) producing CD4+ T cell subsets were increased in BUD patients. In addition, TNFα+CD40L-IFNγ- CD4+ T cells differed between patients and controls (p = 0.034). TNFα+CD40L-IFNγ- CD4+ T cells were correlated with lesion size (p = 0.010) and proportion were higher in ‘slow’ healers compared to ‘fast healers’ (p = 0.030). Conclusions: We were able to identify M. ulcerans-specific CD4+ T cell subsets with specific cytokine profiles. In particular a CD4+ T cell subset, producing TNFα but not IFNγ and CD40L, showed association with lesion size and healing progress. Further studies are required to investigate, if the identified CD4+ T cell subset has the potential to be used as biomarker for diagnosis, severity and/or progression of disease. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
38. Epidemiology of Mansonella perstans in the middle belt of Ghana.
- Author
-
Batsa Debrah, Linda, Nausch, Norman, Serwaa Opoku, Vera, Owusu, Wellington, Mubarik, Yusif, Antwi Berko, Daniel, Wanji, Samuel, Layland, Laura E., Hoerauf, Achim, Jacobsen, Marc, Yaw Debrah, Alexander, and Phillips, Richard O.
- Subjects
EPIDEMIOLOGY ,PARASITIC diseases ,PUBLIC health ,CULICOIDES ,FILARIASIS ,NEMATODE infections - Abstract
Background: Mansonellosis was first reported in Ghana by Awadzi in the 1990s. Co-infections of Mansonella perstans have also been reported in a small cohort of patients with Buruli ulcer and their contacts. However, no study has assessed the exact prevalence of the disease in a larger study population. This study therefore aimed to find out the prevalence of M. perstans infection in some districts in Ghana and to determine the diversity of Culicoides that could be potential vectors for transmission. Methods: From each participant screened in the Asante Akim North (Ashanti Region), Sene West and Atebubu Amantin (Brong Ahafo Region) districts, a total of 70 μl of finger prick blood was collected for assessment of M. perstans microfilariae. Centre for Disease Control (CDC) light traps as well as the Human Landing Catch (HLC) method were used to assess the species diversity of Culicoides present in the study communities. Results: From 2,247 participants, an overall prevalence of 32% was recorded although up to 75% prevalence was demonstrated in some of the communities. Culicoides inornatipennis was the only species of Culicoides caught with the HLC method. By contrast, C. imicola (47%), C. neavei (25%) and C. schultzei (15%) were caught by the CDC light trap method. A wide diversity of other Culicoides spp. was also identified but correlation was only found between the prevalence of C. inornatipennis and M. perstans during the dry season. Conclusions: Here we demonstrate for the first time that M. perstans is highly prevalent in three districts in Ghana. We found a wide spectrum of Culicoides spp. Culicoides inornatipennis was the most anthropophilic and is therefore likely to be the species responsible for transmission of infection but formal proof has yet to be obtained. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
39. Former Buruli Ulcer Patients’ Experiences and Wishes May Serve as a Guide to Further Improve Buruli Ulcer Management.
- Author
-
Velink, Anita, Woolley, Rebecca J., Phillips, Richard O., Abass, Kabiru M., van der Werf, Tjip S., Agumah, Emmanuel, de Zeeuw, Janine, Klis, Sandor, and Stienstra, Ymkje
- Subjects
BURULI ulcer ,MYCOBACTERIUM ,TROPICAL medicine ,RIFAMPIN ,STREPTOMYCIN ,SOFT tissue infections ,THERAPEUTICS - Abstract
Background: Buruli ulcer (BU), caused by Mycobacterium ulcerans, is a neglected tropical disease frequently leading to permanent disabilities. The ulcers are treated with rifampicin and streptomycin, wound care and, if necessary surgical intervention. Professionals have exclusively shaped the research agenda concerning management and control, while patients’ perspective on priorities and preferences have not explicitly been explored or addressed. Methodology/Principal findings: To get insight into patient perception of the management and control of Buruli ulcer a mixed methods research design was applied with a questionnaire and focus group discussions among former BU patients. Data collection was obtained in collaboration with a local team of native speakers in Ghana. A questionnaire was completed by 60 former patients and four focus group discussions were conducted with eight participants per group. Former patients positively evaluated both the effectiveness of the treatment and the financial contribution received for the travel costs to the hospitals. Pain experienced during treatment procedures, in particular wound care and the streptomycin injections, and the side-effects of the treatment were negatively evaluated. Former patients considered the development of preventive measures and knowledge on the transmission as priorities. Additionally, former patients asked for improved accessibility of health services, counselling and economic support. Conclusions: These findings can be used to improve clinical management and to guide the international research agenda. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
40. Experiences of Pain and Expectations for Its Treatment among Former Buruli Ulcer Patients.
- Author
-
Woolley, Rebecca J., Velink, Anita, Phillips, Richard O., Thompson, William A., Abass, K. Mohammed, van der Werf, Tjip S., de Zeeuw, Janine, and Stienstra, Ymkje
- Published
- 2016
- Full Text
- View/download PDF
41. High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis/rifampicin in Ghana.
- Author
-
Boakye-Appiah, Justice K., Steinmetz, Alexis R., Pupulampu, Peter, Ofori-Yirenkyi, Stephen, Tetteh, Ishmael, Frimpong, Michael, Oppong, Patrick, Opare-Sem, Ohene, Norman, Betty R., Stienstra, Ymkje, van der Werf, Tjip S., Wansbrough-Jones, Mark, Bonsu, Frank, Obeng-Baah, Joseph, and Phillips, Richard O.
- Abstract
Objective/Background Drug-resistant strains of tuberculosis (TB) represent a major threat to global TB control. In low- and middle-income countries, resource constraints make it difficult to identify and monitor cases of resistance using drug susceptibility testing and culture. Molecular assays such as the GeneXpert Mycobacterium tuberculosis /rifampicin may prove to be a cost-effective solution to this problem in these settings. The objective of this study is to evaluate the use of GeneXpert in the diagnosis of pulmonary TB since it was introduced into two tertiary hospitals in Ghana in 2013. Methods A 2-year retrospective audit of clinical cases involving patients who presented with clinically suspected TB or documented TB not improving on standard therapy and had samples sent for GeneXpert testing. Results GeneXpert identified 169 cases of TB, including 17 cases of rifampicin-resistant TB. Of the seven cases with final culture and drug susceptibility testing results, six demonstrated further drug resistance and five of these were multidrug-resistant TB. Conclusion These findings call for a scale-up of TB control in Ghana and provide evidence that the expansion of GeneXpert may be an optimal means to improve case finding and guide treatment of drug-resistant TB in this setting. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
42. Pulmonary aspergilloma: An evasive disease.
- Author
-
Ofori, Afua, Steinmetz, Alexis R., Akaasi, John, Asafu Adjaye Frimpong, George A., Norman, Betty R., Obeng-Baah, Joseph, Bedu-Addo, George, and Phillips, Richard O.
- Abstract
Aspergillomas are often misdiagnosed as tuberculosis (TB) in developing countries where the prevalence of TB is high, hemoptysis is often equated with TB, and most patients are diagnosed clinically. This report describes the case of a patient being treated for smear-negative TB who presented with hemoptysis and was found to have an aspergilloma. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
43. Genetic Susceptibility and Predictors of Paradoxical Reactions in Buruli Ulcer.
- Author
-
Barogui, Yves Thierry, Klis, Sandor-Adrian, Johnson, Roch Christian, Phillips, Richard O., van der Veer, Eveline, van Diemen, Cleo, van der Werf, Tjip S., and Stienstra, Ymkje
- Subjects
BURULI ulcer ,TUBERCULOSIS ,HANSEN'S disease ,VITAMIN D ,RADIOIMMUNOASSAY ,LOGISTIC regression analysis - Abstract
Introduction: Buruli ulcer (BU) is the third most frequent mycobacterial disease in immunocompetent persons after tuberculosis and leprosy. During the last decade, eight weeks of antimicrobial treatment has become the standard of care. This treatment may be accompanied by transient clinical deterioration, known as paradoxical reaction. We investigate the incidence and the risks factors associated with paradoxical reaction in BU. Methods: The lesion size of participants was assessed by careful palpation and recorded by serial acetate sheet tracings. For every time point, surface area was compared with the previous assessment. All patients received antimicrobial treatment for 8 weeks. Serum concentration of 25-hydroxyvitamin D, the primary indicator of vitamin D status, was determined in duplex for blood samples at baseline by a radioimmunoassay. We genotyped four polymorphisms in the SLC11A1 gene, previously associated with susceptibility to BU. For testing the association of genetic variants with paradoxical responses, we used a binary logistic regression analysis with the occurrence of a paradoxical response as the dependent variable. Results: Paradoxical reaction occurred in 22% of the patients; the reaction was significantly associated with trunk localization (p = .039 by Χ
2 ), larger lesions (p = .021 by Χ2 ) and genetic factors. The polymorphisms 3’UTR TGTG ins/ins (OR 7.19, p < .001) had a higher risk for developing paradoxical reaction compared to ins/del or del/del polymorphisms. Conclusions: Paradoxical reactions are common in BU. They are associated with trunk localization, larger lesions and polymorphisms in the SLC11A1 gene. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
44. Next-Generation Sequencing Reveals Frequent Opportunities for Exposure to Hepatitis C Virus in Ghana.
- Author
-
Forbi, Joseph C., Layden, Jennifer E., Phillips, Richard O., Mora, Nallely, Xia, Guo-liang, Campo, David S., Purdy, Michael A., Dimitrova, Zoya E., Owusu, Dorcas O., Punkova, Lili T., Skums, Pavel, Owusu-Ofori, Shirley, Sarfo, Fred Stephen, Vaughan, Gilberto, Roh, Hajung, Opare-Sem, Ohene K., Cooper, Richard S., and Khudyakov, Yury E.
- Subjects
HEPATITIS C ,GHANAIANS ,LIVER disease diagnosis ,GENOTYPES ,DISEASE prevalence ,DISEASES ,PATIENTS - Abstract
Globally, hepatitis C Virus (HCV) infection is responsible for a large proportion of persons with liver disease, including cancer. The infection is highly prevalent in sub-Saharan Africa. West Africa was identified as a geographic origin of two HCV genotypes. However, little is known about the genetic composition of HCV populations in many countries of the region. Using conventional and next-generation sequencing (NGS), we identified and genetically characterized 65 HCV strains circulating among HCV-positive blood donors in Kumasi, Ghana. Phylogenetic analysis using consensus sequences derived from 3 genomic regions of the HCV genome, 5'-untranslated region, hypervariable region 1 (HVR1) and NS5B gene, consistently classified the HCV variants (n = 65) into genotypes 1 (HCV-1, 15%) and genotype 2 (HCV-2, 85%). The Ghanaian and West African HCV-2 NS5B sequences were found completely intermixed in the phylogenetic tree, indicating a substantial genetic heterogeneity of HCV-2 in Ghana. Analysis of HVR1 sequences from intra-host HCV variants obtained by NGS showed that three donors were infected with >1 HCV strain, including infections with 2 genotypes. Two other donors share an HCV strain, indicating HCV transmission between them. The HCV-2 strain sampled from one donor was replaced with another HCV-2 strain after only 2 months of observation, indicating rapid strain switching. Bayesian analysis estimated that the HCV-2 strains in Ghana were expanding since the 16
th century. The blood donors in Kumasi, Ghana, are infected with a very heterogeneous HCV population of HCV-1 and HCV-2, with HCV-2 being prevalent. The detection of three cases of co- or super-infections and transmission linkage between 2 cases suggests frequent opportunities for HCV exposure among the blood donors and is consistent with the reported high HCV prevalence. The conditions for effective HCV-2 transmission existed for ~ 3–4 centuries, indicating a long epidemic history of HCV-2 in Ghana. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
45. Assessment and Treatment of Pain during Treatment of Buruli Ulcer.
- Author
-
de Zeeuw, Janine, Alferink, Marike, Barogui, Yves T., Sopoh, Ghislain, Phillips, Richard O., van der Werf, Tjip S., Loth, Susanne, Molenbuur, Bouwe, Plantinga, Mirjam, Ranchor, Adelita V., and Stienstra, Ymkje
- Subjects
CHRONIC pain treatment ,BURULI ulcer ,ANALGESICS ,ANTIBIOTICS ,TROPICAL medicine ,THERAPEUTICS - Abstract
Background: Buruli ulcer (BU) is described as a relatively painless condition; however clinical observations reveal that patients do experience pain during their treatment. Knowledge on current pain assessment and treatment in BU is necessary to develop and implement a future guideline on pain management in BU. Methodology: A mixed methods approach was used, consisting of information retrieved from medical records on prescribed pain medication from Ghana and Benin, and semi-structured interviews with health care personnel (HCP) from Ghana on pain perceptions, assessment and treatment. Medical records (n = 149) of patients treated between 2008 and 2012 were collected between November 2012 and August 2013. Interviews (n = 11) were audio-taped, transcribed verbatim and qualitatively analyzed. Principal Findings: In 113 (84%) of the 135 included records, pain medication, mostly simple analgesics, was prescribed. In 48% of the prescriptions, an indication was not documented. HCP reported that advanced BU could be painful, especially after wound care and after a skin graft. They reported not be trained in the assessment of mild pain. Pain recognition was perceived as difficult, as patients were said to suppress or to exaggerate pain, and to have different expectations regarding acceptable pain levels. HCP reported a fear of side effects of pain medication, shortage and irregularities in the supply of pain medication, and time constraints among medical doctors for pain management. Conclusions: Professionals perceived BU disease as potentially painful, and predominantly focused on severe pain. Our study suggests that pain in BU deserves attention and should be integrated in current treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
46. Pain Associated with Wound Care Treatment among Buruli Ulcer Patients from Ghana and Benin.
- Author
-
Alferink, Marike, de Zeeuw, Janine, Sopoh, Ghislain, Agossadou, Chantal, Abass, Karibu M., Phillips, Richard O., Loth, Susanne, Jutten, Emma, Barogui, Yves T., Stewart, Roy E., van der Werf, Tjip S., Stienstra, Ymkje, and Ranchor, Adelita V.
- Subjects
PAIN perception ,BURULI ulcer ,MYCOBACTERIUM ,CLINICAL trials ,SCIENTIFIC observation - Abstract
Buruli ulcer (BU) is a necrotizing skin disease caused by Mycobacterium ulcerans. People living in remote areas in tropical Sub Saharan Africa are mostly affected. Wound care is an important component of BU management; this often needs to be extended for months after the initial antibiotic treatment. BU is reported in the literature as being painless, however clinical observations revealed that some patients experienced pain during wound care. This was the first study on pain intensity during and after wound care in BU patients and factors associated with pain. In Ghana and Benin, 52 BU patients above 5 years of age and their relatives were included between December 2012 and May 2014. Information on pain intensity during and after wound care was obtained during two consecutive weeks using the Wong-Baker Pain Scale. Median pain intensity during wound care was in the lower range (Mdn = 2, CV = 1), but severe pain (score > 6) was reported in nearly 30% of the patients. Nevertheless, only one patient received pain medication. Pain declined over time to low scores 2 hours after treatment. Factors associated with higher self-reported pain scores were; male gender, fear prior to treatment, pain during the night prior to treatment, and pain caused by cleaning the wound. The general idea that BU is painless is incorrect for the wound care procedure. This procedural pain deserves attention and appropriate intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
47. Persisting Social Participation Restrictions among Former Buruli Ulcer Patients in Ghana and Benin.
- Author
-
de Zeeuw, Janine, Omansen, Till F., Douwstra, Marlies, Barogui, Yves T., Agossadou, Chantal, Sopoh, Ghislain E., Phillips, Richard O., Johnson, Christian, Abass, K. Mohammed, Saunderson, Paul, Dijkstra, Pieter U., van der Werf, Tjip S., and Stientstra, Ymkje
- Subjects
SOCIAL participation ,BURULI ulcer ,SOCIAL impact ,DISABILITIES ,PUBLIC spaces ,FUNCTIONAL status - Abstract
Background: Buruli ulcer may induce severe disabilities impacting on a person's well-being and quality of life. Information about long-term disabilities and participation restrictions is scanty. The objective of this study was to gain insight into participation restrictions among former Buruli ulcer patients in Ghana and Benin. Methods: In this cross-sectional study, former Buruli ulcer patients were interviewed using the Participation Scale, the Buruli Ulcer Functional Limitation Score to measure functional limitations, and the Explanatory Model Interview Catalogue to measure perceived stigma. Healthy community controls were also interviewed using the Participation Scale. Trained native interviewers conducted the interviews. Former Buruli ulcer patients were eligible for inclusion if they had been treated between 2005 and 2011, had ended treatment at least 3 months before the interview, and were at least 15 years of age. Results: In total, 143 former Buruli ulcer patients and 106 community controls from Ghana and Benin were included in the study. Participation restrictions were experienced by 67 former patients (median score, 30, IQR; 23;43) while 76 participated in social life without problems (median score 5, IQR; 2;9). Most restrictions encountered related to employment. Linear regression showed being female, perceived stigma, functional limitations, and larger lesions (category II) as predictors of more participation restrictions. Conclusion: Persisting participation restrictions were experienced by former BU patients in Ghana and Benin. Most important predictors of participation restrictions were being female, perceived stigma, functional limitations and larger lesions. Author Summary: Disabilities among Buruli ulcer patients remain a problem. Previous studies revealed contractures, deformities and functional limitations in daily life after treatment. According to the International Classification of Functioning, Disability and Health, disabilities occur not only at the physical and activity level but at the participation level (participation restrictions) as well. The latter are the social consequences of the disease such as problems in relationships, going to festivals and visiting public places. This study focused on participation restrictions by using the Participation Scale among former Buruli ulcer patients and healthy persons residing in two areas endemic for Buruli ulcer in Ghana and Benin. This study showed that almost half of the former Buruli ulcer patients encountered problems in social life, especially related to employment. In addition, the results suggest that being female, perceived stigma, functional limitations and a larger lesion (category II) predict participation restrictions. These findings indicate that rehabilitation programs should not only focus on physical disabilities but also on participation after completion of medical treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
48. Psychometric Properties of the Participation Scale among Former Buruli Ulcer Patients in Ghana and Benin.
- Author
-
de Zeeuw, Janine, Douwstra, Marlies, Omansen, Till F., Sopoh, Ghislain E., Johnson, Christian, Phillips, Richard O., Alferink, Marike, Saunderson, Paul, Van der Werf, Tjip S., Dijkstra, Pieter U., and Stienstra, Ymkje
- Subjects
BURULI ulcer ,PSYCHOMETRICS ,SOCIAL participation ,MEDICAL terminology ,DISABILITIES - Abstract
Background: Buruli ulcer is a stigmatising disease treated with antibiotics and wound care, and sometimes surgical intervention is necessary. Permanent limitations in daily activities are a common long term consequence. It is unknown to what extent patients perceive problems in participation in social activities. The psychometric properties of the Participation Scale used in other disabling diseases, such as leprosy, was assessed for use in former Buruli ulcer patients. Methods: Former Buruli ulcer patients in Ghana and Benin, their relatives, and healthy community controls were interviewed using the Participation Scale, Buruli Ulcer Functional Limitation Score, and the Explanatory Model Interview Catalogue to measure stigma. The Participation Scale was tested for the following psychometric properties: discrimination, floor and ceiling effects, internal consistency, inter-item correlation, item-total correlation and construct validity. Results: In total 386 participants (143 former Buruli ulcer patients with their relatives (137) and 106 community controls) were included in the study. The Participation Scale displayed good discrimination between former Buruli ulcer patients and healthy community controls. No floor and ceiling effects were found. Internal consistency (Cronbach's alpha) was 0.88. In Ghana, mean inter-item correlation of 0.29 and item-total correlations ranging from 0.10 to 0.69 were found while in Benin, a mean inter-item correlation of 0.28 was reported with item-total correlations ranging from −0.08 to 0.79. With respect to construct validity, 4 out of 6 hypotheses were not rejected, though correlations between various constructs differed between countries. Conclusion: The results indicate the Participation Scale has acceptable psychometric properties and can be used for Buruli ulcer patients in Ghana and Benin. Future studies can use this Participation Scale to evaluate the long term restrictions in participation in daily social activities of former BU patients. Author Summary: Buruli ulcer is a stigmatising condition caused by infection with Mycobacterium ulcerans. Besides the long term medical consequences, Buruli ulcer may lead to participation restrictions in social life. The Participation Scale intends to assess perceived participation restrictions; however, this instrument has been developed in patients affected by leprosy and other disabling conditions, and has never been used before among Buruli ulcer patients. We aimed to analyze the reliability and validity of the Participation Scale among former Buruli ulcer patients in Ghana and Benin. This study included former Buruli ulcer patients from 2 different treatment sites, along with their relatives and healthy community controls residing in similar geographical areas. Former Buruli ulcer patients were interviewed using the Participation Scale, Buruli Ulcer Functional Limitation Score, and the Explanatory Model Interview Catalogue to measure stigma. Relatives and healthy community controls were interviewed using the Participation Scale. We tested the Participation Scale for discrimination, floor and ceiling effects, internal consistency, inter-item correlation, item-total correlation and construct validity. The results of the analysis suggest that the Participation Scale has acceptable psychometric properties. As such, the instrument can be used to assess participation restrictions among former Buruli ulcer patients in Ghana and Benin. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
49. Good Quality of Life in Former Buruli Ulcer Patients with Small Lesions: Long-Term Follow-up of the BURULICO Trial.
- Author
-
Klis, Sandor, Ranchor, Adelita, Phillips, Richard O., Abass, Kabiru M., Tuah, Wilson, Loth, Susanne, Velding, Kristien, van der Werf, Tjip S., and Stienstra, Ymkje
- Subjects
BURULI ulcer ,QUALITY of life ,CLINICAL drug trials ,FUNCTIONAL status ,RANDOMIZED controlled trials ,SKIN diseases - Abstract
Background: Buruli Ulcer is a tropical skin disease caused by Mycobacterium ulcerans, which, due to scarring and contractures can lead to stigma and functional limitations. However, recent advances in treatment, combined with increased public health efforts have the potential to significantly improve disease outcome. Objectives: To study the Quality of Life (QoL) of former Buruli Ulcer patients who, in the context of a randomized controlled trial, reported early with small lesions (cross-sectional diameter <10 cm), and received a full course of antibiotic treatment. Methods: 127 Participants of the BURULICO drug trial in Ghana were revisited. All former patients aged 16 or older completed the Dermatology Life Quality Index (DLQI) and the abbreviated World Health Organization Quality of Life scale (WHOQOL-BREF). The WHOQOL-BREF was also administered to 82 matched healthy controls. Those younger than 16 completed the Childrens' Dermatology Life Quality Index (CDLQI) only. Results: The median (Inter Quartile Range) score on the DLQI was 0 (0–4), indicating good QoL. 85% of former patients indicated no effect, or only a small effect of the disease on their current life. Former patients also indicated good QoL on the physical and psychological domains of the WHOQOL-BREF, and scored significantly higher than healthy controls on these domains. There was a weak correlation between the DLQI and scar size (ρ = 0.32; p<0.001). Conclusions: BU patients who report early with small lesions and receive 8 weeks of antimicrobial therapy have a good QoL at long-term follow-up. These findings contrast with the debilitating sequelae often reported in BU, and highlight the importance of early case detection. Author Summary: Buruli ulcer is an infectious skin disease, mainly occurring in West Africa. It usually starts with a small nodule that over the course of weeks progresses into an ulcer. Effective treatment with antibiotics is available, but patients often report to the hospital late, and there is a serious risk of scarring, contractures and functional limitations of the affected body parts. Although it is often reported that Buruli ulcers can have serious sequelae, the quality of life of former Buruli ulcer patients has not been studied before. In this study we assessed the quality of life of healed Buruli ulcer patients that took part in a drug trial between 2006 and 2009, which only included small and early lesions. On follow-up, we found that most scars were small and functional limitations were rare, and that both general and skin specific Quality of Life was good. Our results demonstrate the potential of the combination of early detection and proper antibiotic treatment of Buruli ulcer and hence stress the importance of public health efforts aimed at diagnosing the disease in its early stage, and providing standardized treatment in endemic areas. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
50. A Severe Case of Buruli Ulcer Disease with Pleural Effusions.
- Author
-
Sarfo, Fred S., Thompson, William, Phillips, Richard O., Paintsil, Albert, Abass, Mohammed K., Frimpong, Michael, Abotsi, Justice, Asiedu, Kingsley, and Wansbrough-Jones, Mark H.
- Subjects
PLEURAL effusions ,STEROID drugs ,BURULI ulcer ,TREATMENT effectiveness - Abstract
This article discusses a severe case of Buruli ulcer disease in an 8-year-old girl from Ghana. The patient initially had a painless nodule on her chest that rapidly increased in size. After seeking medical attention, she was diagnosed with Buruli ulcer disease and started on antibiotic therapy. However, two weeks into treatment, she developed pleural effusions, which is a rare complication of the disease. The patient was successfully treated with thoracocentesis, steroid therapy, and surgical therapy. The article highlights the challenges and successes of managing Buruli ulcer disease in rural communities and discusses the phenomenon of paradoxical reactions during antibiotic therapy. [Extracted from the article]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.